Skip To Content

Blogs

Sharing perspectives leads to greater understanding and fuels innovation.

The ​Optum Insights ​blog is where we share our perspective and challenge preconceptions to clear a new path forward.

April 07, 2022 · Medicare Insights Team
On Wednesday, April 13, 2022, the Centers for Medicare and Medicaid Services (CMS) will host an overview of the new “Go Paperless” feature available in the Medicare Secondary Payer Recovery Portal (MSPRP). Read more...
March 30, 2022 · Public Policy & Regulatory Affairs Team
Read more...
March 29, 2022 · Medicare Insights Team
On March 15, the Centers for Medicare and Medicaid Services (CMS) released an updated Workers’ Compensation Medicare Set-Aside Arrangement (WCMSA) Reference Guide (Version 3.6). Read more...
March 09, 2022 · Public Policy & Regulatory Affairs Team
Read more...
March 08, 2022 · Medicare Insights Team
On March 1, 2022, Centers for Medicare and Medicaid Services (CMS) submitted the following two Rules to the White House Office of Regulatory Information and Affairs (OIRA) for review and approval. Read more...
February 21, 2022 · Medicare Insights Team
In response to the most recent Workers’ Compensation Medicare Set Aside (WCMSA) Reference Guide, on February 17, 2022, The Centers for Medicare and Medicaid Services (CMS) hosted a webinar to provide a much-anticipated update on non-CMS-approved Medicare Set-Aside (MSA) products. CMS’ John Jenkins, Health Insurance Specialist, reviewed topics including Evidence-Based MSAs, Non-Submit MSAs and Compromise MSA. Read more...
February 17, 2022 · Clinical Team
The U.S. Food and Drug Administration (FDA) issued a warning on January 12, 2022, regarding a potential risk of dental problems with orally-dissolving buprenorphine medications. Buprenorphine is a mixed opiate agonist-antagonist used to treat opioid use disorder (OUD) and pain. Read more...
February 17, 2022 · Clinical Team
The U.S. Food and Drug Administration (FDA) issued a warning on January 12, 2022, regarding a potential risk of dental problems with orally-dissolving buprenorphine medications. Buprenorphine is a mixed opiate agonist-antagonist used to treat opioid use disorder (OUD) and pain. Read more...
<< Previous      Next >>
Page 2 of 19

Subscribe today to receive our latest blogs, articles, podcasts and more.